[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]

[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]

Tamoxifen administered in patients after breast cancer surgery is one of the most effective adjuvant treatments in this pathology. A large number of randomized studies including thousands of patients allowed to quantify the treatment benefits in terms of recurrence, contralateral breast cancer and o...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Davies, C, Arriagada, R, Ziegler, A, Peralta, O
Format:	Journal article
Język:	Spanish; Castilian
Wydane:	1998

Podobne zapisy

[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed]
od: Davies, C, i wsp.
Wydane: (1997)

Variation in use of adjuvant tamoxifen.
od: Davies, C, i wsp.
Wydane: (1998)

Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.
od: Earl, H, i wsp.
Wydane: (1996)

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
od: Gelber, R, i wsp.
Wydane: (1996)

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
od: Dowsett, M, i wsp.
Wydane: (2009)

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
od: Early Breast Cancer Trialists' Collaborative Group
Wydane: (1988)

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
od: Jaime D. Lewis, i wsp.
Wydane: (2014-11-01)

Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.
od: Mustafa Al-Mubarak, i wsp.
Wydane: (2014-01-01)

Tamoxifen therapy for patients with breast cancer - Authors' reply.
od: Davies, C, i wsp.
Wydane: (2013)

Tamoxifen for Breast Cancer
od: A Karn, i wsp.
Wydane: (2010-03-01)

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.
od: Davies, C
Wydane: (2004)

Early breast cancer: How long should tamoxifen continue?
od: Davies, C, i wsp.
Wydane: (1999)

Which adjuvant endocrine therapy for ER-positive non-metastatic breast cancer? EBCTCG-2000 update: Tamoxifen, castration, LHRH-agonists
od: Davies, C, i wsp.
Wydane: (2002)

Early breast cancer: How long should tamoxifen continue?
od: Davies, C, i wsp.
Wydane: (1998)

Tamoxifen for early breast cancer: better late than never.
od: Gray, R, i wsp.
Wydane: (2000)

Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy
od: Lim, I-Liang, i wsp.
Wydane: (2018)

Features of ovarian steroidogenesis and endometrial hypertrophy during adjuvant therapy with tamoxifen in premenopausal patients with hormone-dependent breast cancer
od: A. Yu. Goryainova, i wsp.
Wydane: (2023-05-01)

10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS
od: Davies, C, i wsp.
Wydane: (2017)

WITHDRAWN: Tamoxifen for early breast cancer.
od: Clarke, M
Wydane: (2008)

Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
od: Aline Cruz, i wsp.
Wydane: (2017-12-01)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
od: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Wydane: (2011)

Tamoxifen in breast conservation therapy.
od: Lee, K, i wsp.
Wydane: (1995)

Results of combination treatment using docetaxel in an adjuvant chemotherapy regimen for resectable breast cancer
od: L. V. Bolotina, i wsp.
Wydane: (2014-07-01)

The gut microbiota during tamoxifen therapy in patients with breast cancer
od: Lars E. Hillege, i wsp.
Wydane: (2025-03-01)

Leuprolide Acetate Treatment for Ovarian Cysts in Breast Cancer Patients Under Tamoxifen Therapy
od: Şafak Yılmaz Baran, i wsp.
Wydane: (2022-12-01)

Adjuvant treatment for breast cancer
od: Flatley, M, i wsp.
Wydane: (2019)

EFFECTS OF ADJUVANT TAMOXIFEN AND OF CYTOTOXIC THERAPY ON MORTALITY IN EARLY BREAST-CANCER - AN OVERVIEW OF 61 RANDOMIZED TRIALS AMONG 28,896 WOMEN
od: Peto, R
Wydane: (1989)

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up
od: Helena Fohlin, i wsp.
Wydane: (2024-07-01)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
od: Davies, C, i wsp.
Wydane: (2013)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
od: Mele, T, i wsp.
Wydane: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
od: Mele, T, i wsp.
Wydane: (2010)

Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data
od: Bianca Kruger, i wsp.
Wydane: (2024-03-01)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
od: Davies, C, i wsp.
Wydane: (2013)

Tamoxifen for early breast cancer: an overview of the randomised trials
od: Early Breast Cancer Trialists' Collaborative Group
Wydane: (1998)

Modern breast cancer therapy: from tamoxifen to T-cell engineering
od: Yu. A. Shevchenko, i wsp.
Wydane: (2022-11-01)

Sox2 promotes tamoxifen resistance in breast cancer cells
od: Marco Piva, i wsp.
Wydane: (2013-10-01)

Laparoscopic bilateral salpingo-oophorectomy for recurrent ovarian endometriotic cysts in a woman taking adjuvant tamoxifen for breast cancer: A case report
od: Hajime Takeuchi, i wsp.
Wydane: (2024-10-01)

The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer
od: Iveta Kolářová, i wsp.
Wydane: (2024-02-01)

Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model
od: Angel Pulido-Capiz, i wsp.
Wydane: (2024-09-01)

Ultrasonic, hysteroscopic and histological evaluation of the endometrium in women receiving tamoxifen for breast cancer
od: N. S. Melnikova, i wsp.
Wydane: (2014-07-01)